Pancreatic Cancer Research

Clinical trialPhase 1Terminated

Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors

A Phase I Dose Escalation Study of NMS-03305293 in Adult Patients with Selected Advanced/Metastatic Solid Tumors

Outcome
Stopped earlyThe study closure is related to sponsor decision to shift towards the clinical development of NMS-03305293 in combination in a broader range of indication and not based on emerging safety or efficacy concerns. (Business decision)
Phase
Phase 1
Status
Terminated
Study type
Interventional
Start
25 November 2019
Ended
16 May 2024
Enrollment
52 participants
Sites
10
Primary outcomes
Number of Participants with first-cycle dose limiting toxicity
Sponsor type
Industry
Results posted
No
Last update
19 September 2024

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

Phase I, first-in-human, open-label, multicenter, dose-escalation and dose expansion study with the aim of exploring safety, tolerability and preliminary antitumor activity of NMS-03305293 (a PARP inhibitor) as single agent in adult patients with selected advanced/metastatic, relapsed/refractory solid tumors who have exhausted standard treatment options or for whom standard therapy is considered unsuitable.